The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Press Release

2 Feb

2023

POINT today announced management will participate in the following upcoming investor conferences

Press Release

12 Jan

2023

Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance